InVivoMAb anti-mouse CTLA-4 (CD152)

Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatment. Zippelius A et al., 2015 Mar, Cancer Immunol Res

Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies. Dai M et al., 2015 Mar 1, Clin Cancer Res

Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells. Mueller P et al., 2014 Aug, Cancer Immunol Res

ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis. Condamine T et al., 2014 Jun, J Clin Invest

Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity. Redmond WL et al., 2014 Feb, Cancer Immunol Res

Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin. Wei H et al., 2013, PLoS One

Activating Fc gamma receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. Bulliard Y et al., 2013 Aug 26, J Exp Med

Long-lasting complete regression of established mouse tumors by counteracting Th2 inflammation. Dai M et al., 2013 May, J Immunother

Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma. Hooijkaas A et al., 2012 Aug 1, Oncoimmunology

Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Balachandran VP et al., 2011 Aug 28, Nat Med